The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Muted movement reflects consolidation phase as investors await earnings triggers
Board approves five-year appointment, subject to shareholder nod through postal ballot
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The change of name has been carried on pursuant to the Scheme of Amalgamation
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
Subscribe To Our Newsletter & Stay Updated
